cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2021-36-4-45-51cardiotomsk-1282Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESКардиогенный шок – что нового?Cardiogenic shock: What’s new?https://orcid.org/0000-0001-5152-2106ПантелеевО. О.PanteleevO. O.

 младший научный сотрудник, отделение неотложной кардиологии; ассистент кафедры кардиологии, Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации

 634012, Российская Федерация, Томск, ул. Киевская, 111а 

Junior Research Scientist, Department of Emergency Cardiology; Assistant Professor, Department of Cardiology, Continuous Medical Education Faculty, Siberian State Medical University 

 111a, Kievskaya str., Tomsk, 634012, Russian Federation 

panteleev.o.o@yandex.ruhttps://orcid.org/0000-0002-4358-7329РябовВ. В.RyabovV. V.

 д-р мед. наук, заведующий отделением неотложной кардиологии, заместитель директора по научной и лечебной работе; доцент, заведующий кафедрой кардиологии,Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации; ведущий научный сотрудник, лаборатория трансляционной и клеточной биомедицины, Национальный  исследовательский Томский государственный университет

 634012, Российская Федерация, Томск, ул. Киевская, 111а 

Dr. Sci. (Med.), Head of Department of Emergency Cardiology; Associate Professor, Department of Cardiology, Continuous Medical Education Faculty,Siberian State Medical University; Leading Research Scientist, Laboratory ofTranslational Cellular and Molecular Biomedicine, National Research TomskState University 

 111a, Kievskaya str., Tomsk, 634012, Russian Federation 

rvvt@cardio-tomsk.ruНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation2021010120223644551Copyright © Пантелеев О.О., Рябов В.В., 20222022Пантелеев О.О., Рябов В.В.Panteleev O.O., Ryabov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1282

 Отсутствие снижения летальности при кардиогенном шоке (КШ) в течение последнего десятилетия, несмотря на большое количество исследований проблемы и достигнутые успехи в лечении инфаркта миокарда (ИМ), определяет необходимость поиска новых подходов к исследованию  проблемы с целью выявления новых возможностей для изменения сложившейся ситуации. В статье анализируется  опыт завершившихся клинических изысканий,  характеризуются перспективные исследования,  посвященные лечению КШ. 

 Cardiogenic shock mortality did not decrease over the past decade despite the large number of studies focusing on the problem and the achieved success in the treatment of myocardial infarction. This provides rationale for search for new approaches to studying the problem in order to identify new opportunities to change the current situation. The article analyzes the experience of completed clinical trials and characterizes prospective studies on the treatment of  cardiogenic shock. 

кардиогенный шокмеханическая поддержка кровообращениялетальностьcardiogenic shockmechanical circulatory supportlethalityReferencesGlobal, regional, and national age-sex specifi c all-cause and cause-specifi c mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. DOI: 10.1016/S0140-6736(14)61682-2.Global, regional, and national age-sex specifi c all-cause and cause-specifi c mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. DOI: 10.1016/S0140-6736(14)61682-2.Pole D.J., Thompson P.L., Woodings T.L., McCall M.G., Reader R. Acute myocardial infarction: Оne year follow-up of 1138 cases from the Perth Community Coronary Register. Aust. N. Z. J. Med. 1976;6(5):437–440. DOI: 10.1111/j.1445-5994.1976.tb03031.x.Pole D.J., Thompson P.L., Woodings T.L., McCall M.G., Reader R. Acute myocardial infarction: Оne year follow-up of 1138 cases from the Perth Community Coronary Register. Aust. N. Z. J. Med. 1976;6(5):437–440. DOI: 10.1111/j.1445-5994.1976.tb03031.x.Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the fi rst year in survivors of acute myocardial infarction: A systematic review. BMC Cardiovasc. Disord. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9.Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the fi rst year in survivors of acute myocardial infarction: A systematic review. BMC Cardiovasc. Disord. 2017;17(1):53. DOI: 10.1186/s12872-017-0482-9.Григорьев Е.В., Баутин А.Е., Киров М.Ю., Шукевич Д.Л., Корнелюк Р.А. Кардиогенный шок при остром коронарном синдроме: современное состояние проблемы диагностики и интенсивной терапии. Вестник интенсивной терапии им. А.И. Салтанова. 2020;2:73–85. DOI: 10.21320/1818-474X-2020-2-73-85.Grigoryev E.V., Bautin A.E., Kirov M.Yu., Shukevich D.L., Kornelyuk R.A. Cardiogenic shock associated with acute coronary syndrome: The current state of the problem of diagnostics and intensive care. Article. Annals of Critical Care. 2020;2:73–85 (In Russ.). DOI: 10.21320/1818-474X-2020-2-73-85.Holmes D.R. Jr., Bates E.R., Kleiman N.S., Sadowski Z., Horgan J.H., Morris D.C. et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J. Am. Coll. Cardiol. 1995;26(3):668–674. DOI: 10.1016/0735-1097(95)00215-p.Holmes D.R. Jr., Bates E.R., Kleiman N.S., Sadowski Z., Horgan J.H., Morris D.C. et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J. Am. Coll. Cardiol. 1995;26(3):668–674. DOI: 10.1016/0735-1097(95)00215-p.Karnash S.L., Granger C.B., White H.D., Woodlief L.H., Topol E.J., Califf R.M. Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J. Am. Coll. Cardiol. 1995;26(7):1651–1656. DOI: 10.1016/0735-1097(95)00386-x.Karnash S.L., Granger C.B., White H.D., Woodlief L.H., Topol E.J., Califf R.M. Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J. Am. Coll. Cardiol. 1995;26(7):1651–1656. DOI: 10.1016/0735-1097(95)00386-x.Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med. 1999;341(9):625–634. DOI: 10.1056/NEJM199908263410901.Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med. 1999;341(9):625–634. DOI: 10.1056/NEJM199908263410901.Vetrovec G.W., Anderson M., Schreiber T., Popma J., Lombardi W., Maini B. et al. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am. Heart J. 2018;199:115–121. DOI: 10.1016/j.ahj.2017.09.007.Vetrovec G.W., Anderson M., Schreiber T., Popma J., Lombardi W., Maini B. et al. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am. Heart J. 2018;199:115–121. DOI: 10.1016/j.ahj.2017.09.007.Shah A.H., Puri R., Kalra A. Management of cardiogenic shock complicating acute myocardial infarction: A review. Clin. Cardiol. 2019;42(4):484–493. DOI: 10.1002/clc.23168.Shah A.H., Puri R., Kalra A. Management of cardiogenic shock complicating acute myocardial infarction: A review. Clin. Cardiol. 2019;42(4):484–493. DOI: 10.1002/clc.23168.Menon V., Fincke R. Cardiogenic shock: A summary of the randomized SHOCK trial. Congest. Heart Fail. 2003;9(1):35–39. DOI: 10.1111/j.1751-7133.2003.tb00020.x.Menon V., Fincke R. Cardiogenic shock: A summary of the randomized SHOCK trial. Congest. Heart Fail. 2003;9(1):35–39. DOI: 10.1111/j.1751-7133.2003.tb00020.x.Oeing C.U., Tschöpe C., Pieske B. [The new ESC Guidelines for acute and chronic heart failure 2016]. Herz. 2016;41(8):655–663 (In Germ.). DOI: 10.1007/s00059-016-4496-3.Oeing C.U., Tschöpe C., Pieske B. [The new ESC Guidelines for acute and chronic heart failure 2016]. Herz. 2016;41(8):655–663 (In Germ.). DOI: 10.1007/s00059-016-4496-3.Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393.Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393.Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021;42(14):1289–1367. DOI: 10.1093/eurheartj/ehaa575.Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021;42(14):1289–1367. DOI: 10.1093/eurheartj/ehaa575.Baran D.A., Grines C.L., Bailey S., Burkhoff D., Hall S.A., Henry T.D. et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc. Interv. 2019;94(1):29–37. DOI: 10.1002/ccd.28329.Baran D.A., Grines C.L., Bailey S., Burkhoff D., Hall S.A., Henry T.D. et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc. Interv. 2019;94(1):29–37. DOI: 10.1002/ccd.28329.Jentzer J.C., van Diepen S., Barsness G.W., Henry T.D., Menon V., Rihal C.S. et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J. Am. Coll. Cardiol. 2019;74(17):2117–2128. DOI: 10.1016/j.jacc.2019.07.077.Jentzer J.C., van Diepen S., Barsness G.W., Henry T.D., Menon V., Rihal C.S. et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J. Am. Coll. Cardiol. 2019;74(17):2117–2128. DOI: 10.1016/j.jacc.2019.07.077.Fincke R., Hochman J.S., Lowe A.M., Menon V., Slater J.N., Webb J.G. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J. Am. Coll. Cardiol. 2004;44(2):340–8. DOI: 10.1016/j.jacc.2004.03.060.Fincke R., Hochman J.S., Lowe A.M., Menon V., Slater J.N., Webb J.G. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J. Am. Coll. Cardiol. 2004;44(2):340–8. DOI: 10.1016/j.jacc.2004.03.060.Parissis H., Graham V., Lampridis S., Lau M., Hooks G., Mhandu P.C. IABP: History-evolution-pathophysiology-indications: What we need to know. J. Cardiothorac. Surg. 2016;11(1):122. DOI: 10.1186/s13019-016-0513-0.Parissis H., Graham V., Lampridis S., Lau M., Hooks G., Mhandu P.C. IABP: History-evolution-pathophysiology-indications: What we need to know. J. Cardiothorac. Surg. 2016;11(1):122. DOI: 10.1186/s13019-016-0513-0.Wong A.S.K., Sin S.W.C. Short-term mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation, TandemHeart): a review. Ann. Transl. Med. 2020 Jul;8(13):829. DOI: 10.21037/atm-20-2171.Wong A.S.K., Sin S.W.C. Short-term mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation, TandemHeart): a review. Ann. Transl. Med. 2020 Jul;8(13):829. DOI: 10.21037/atm-20-2171.Den Uil C.A., Daemen J., Lenzen M.J., Maugenest A.M., Joziasse L., van Geuns R.J. et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12(14):1689–1696. DOI: 10.4244/EIJ-D-16-00371.Den Uil C.A., Daemen J., Lenzen M.J., Maugenest A.M., Joziasse L., van Geuns R.J. et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12(14):1689–1696. DOI: 10.4244/EIJ-D-16-00371.Napp L.C., Kühn C., Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42(1):27–44. DOI: 10.1007/s00059-016-4523-4.Napp L.C., Kühn C., Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42(1):27–44. DOI: 10.1007/s00059-016-4523-4.Timóteo A.T., Nogueira M.A., Rosa S.A., Belo A., Ferreira R.C.; ProACS Investigators. Role of intra-aortic balloon pump counterpulsation in the treatment of acute myocardial infarction complicated by cardiogenic shock: Evidence from the Portuguese nationwide registry. Eur. Heart J. Acute Cardiovasc. Care. 2016;5(7):23–31. DOI: 10.1177/2048872615606600.Timóteo A.T., Nogueira M.A., Rosa S.A., Belo A., Ferreira R.C.; ProACS Investigators. Role of intra-aortic balloon pump counterpulsation in the treatment of acute myocardial infarction complicated by cardiogenic shock: Evidence from the Portuguese nationwide registry. Eur. Heart J. Acute Cardiovasc. Care. 2016;5(7):23–31. DOI: 10.1177/2048872615606600.Ouweneel D.M., Eriksen E., Sjauw K.D., van Dongen I.M., Hirsch A., Packer E.J. et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J. Am. Coll. Cardiol. 2017;69(3):278–287. DOI: 10.1016/j.jacc.2016.10.022.Ouweneel D.M., Eriksen E., Sjauw K.D., van Dongen I.M., Hirsch A., Packer E.J. et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J. Am. Coll. Cardiol. 2017;69(3):278–287. DOI: 10.1016/j.jacc.2016.10.022.Basir M.B., Schreiber T.L., Grines C.L., Dixon S.R., Moses J.W., Maini B.S. et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am. J. Cardiol. 2017;119(6):845–851. DOI: 10.1016/j.amjcard.2016.11.037.Basir M.B., Schreiber T.L., Grines C.L., Dixon S.R., Moses J.W., Maini B.S. et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am. J. Cardiol. 2017;119(6):845–851. DOI: 10.1016/j.amjcard.2016.11.037.Stretch R., Sauer C.M., Yuh D.D., Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J. Am. Coll. Cardiol. 2014;64(14):1407–1415. DOI: 10.1016/j.jacc.2014.07.958.Stretch R., Sauer C.M., Yuh D.D., Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J. Am. Coll. Cardiol. 2014;64(14):1407–1415. DOI: 10.1016/j.jacc.2014.07.958.

The authors declare that there are no conflicts of interest present.